- Recruiting
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
Updated: Jun 27, 2022
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (TTI-622-01)
ClinicalTrials.gov Identifier: NCT03530683

Sponsor
Trillium Therapeutics Inc.
Multicenter, open-label, phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in subjects with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma.
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT02899052
Official Title: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma
First Posted : May 21, 2018
https://clinicaltrials.gov/ct2/show/NCT03530683